Overview

Teclistamab-Daratumumab in AL Amyloidosis

Status:
NOT_YET_RECRUITING

Trial end date:
2033-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate whether teclistamab-daratumumab combination is effective and safe in AL amyloidosis. The study treatment is divided into cycles (C) and each cycle is 28 days (D). Study treatment is expected to last 6 months.

Phase:

PHASE2

Details

Lead Sponsor:

Suzanne Lentzsch, MD

Collaborator:

Janssen Pharmaceuticals

Treatments:

daratumumab